Our team after much investigation, do not agree with Adam Feursein after few calls to Cytori spokeswomen.
Sources familiar with the matters, said Lim K.T is Mr Lim Kok Thay, the son of late casino magnate run Genting Group, which boast resorts and casino in Malaysia, Singapore, Hongkong, Philippine, US, UK and Australia. Mr Lim K.T is now the chairman of Genting Grouip (www.genting.com), a conglomerate which is involved in leisure & hospitality, power generation, oil palm plantations, property development, biotechnology and oil & gas business activities. His father Mr Lim Goh Tong had cardiovascular problems. Mr Lim K.T a billionair chairman of Genting, is a Visiting Professor of the UK-based Institure of Biomedical Engineering of Imperial College, UK, it has more Leducq Foundation Transatlantic Networks of Excellent in Cardiovascular Reseach Programs than any other UK institution, He was also appointed the Honorary Professor of Xiamen University.
See below PRnewswiere on Nov 20, 2012
Adam is more concerned about a physical "address," rather than the $531 million deal.
He should lose his journal license...oh that's right, any moron with a keyboard can post an article.
Thanks for your ignorance Adam F-bag.
Sentiment: Strong Buy
actually the "About Lorem Vascular" section of the press release would have been drafted in another way I guess and Cytori would have made clear about the Lorem belonging to Genting.
Actually the "About" section looks like a lie given the fact that the company was incorporated just two weeks ago and already claims to have a headquarter in Beijing and a series of offices in Asia
About Lorem Vascular
Lorem Vascular will be a leader in cardiovascular care with world-class regenerative medicine therapy. Headquartered in Beijing, with offices in Hong Kong, Kuala Lumpur, Singapore, and Melbourne, Lorem Vascular is committed to advancing patient care by transforming the treatment of cardiovascular disease by providing access to innovative medical technology to facilitate regenerative medicine, hospital and physician training and continuing medical education. The Company offers a cutting-edge regenerative medicine platform for treating such things as peripheral vascular disease, acute myocardial infarction and chronic heart disease.
It does have offices in those places. "will be" and "offers" should clue you in that this is a start up venture with deep pockets, international connections, and experience in energy, biotech, gas, foods, etc.
They are not hiding. They are listed in the SEC article. Their place of incorporation and headquarters are listed. The separate name is for clarity and future marketing. This is how business is down. There is nothing hidden. Everything was placed right in front of the SEC and the world for all to see or follow up on. The PR said "will be", if people bought this stock without realizing Lorem Vascular was not J&J, then they will sell because Feurenstein intentionally scared and mislead them.
It could be that this time he is thinking big. Maybe he wants to seat in the driver seat because he thinks there is great potential in vascular diseases. Yes this looks weird but what really matters to me is that these are people with deep pockets and assume they would know what they are doing.